Takahiro Domoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6243247/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glycogen synthase kinaseâ€3β is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Science, 2016, 107, 1363-1372.	1.7	130
2	Glycogen Synthase Kinase $3\hat{l}^2$ in Cancer Biology and Treatment. Cells, 2020, 9, 1388.	1.8	46
3	Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway. Molecular Cancer Therapeutics, 2015, 14, 564-574.	1.9	38
4	Identification of GSK3Î ² inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Scientific Reports, 2019, 9, 10049.	1.6	30
5	Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma. Cancer Science, 2020, 111, 429-440.	1.7	28
6	Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin. Oncotarget, 2016, 7, 77038-77051.	0.8	23
7	Cleavage of hepatocyte growth factor activator inhibitorâ€1 by membraneâ€ŧype MMPâ€1 activates matriptase. Cancer Science, 2012, 103, 448-454.	1.7	22
8	Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction. Oncotarget, 2018, 9, 13337-13352.	0.8	22
9	Glycogen synthase kinaseâ€3β participates in acquired resistance to gemcitabine in pancreatic cancer. Cancer Science, 2020, 111, 4405-4416.	1.7	7
10	Vinculin negatively regulates transcription of MT1-MMP through MEK/ERK pathway. Biochemical and Biophysical Research Communications, 2014, 455, 251-255.	1.0	6
11	Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma. Scientific Reports, 2020, 10, 11807.	1.6	6
12	Membrane-type 1 matrix metalloproteinase regulates fibronectin assembly and N-cadherin adhesion. Biochemical and Biophysical Research Communications, 2014, 450, 1016-1020.	1.0	4
13	Discovery of a Novel Aminocyclopropenone Compound That Inhibits BRD4-Driven Nucleoporin NUP210 Expression and Attenuates Colorectal Cancer Growth. Cells, 2022, 11, 317.	1.8	2